Compounds > troponin i (104-115)
Page last updated: 2024-11-13

troponin i (104-115)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

troponin I (104-115): amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44152811
MeSH IDM0169974

Synonyms (9)

Synonym
ac-gly-lys-phe-lys-arg-pro-pro-leu-arg-arg-val-arg-nh2
98353-69-6
tni peptide (104-115)
n-acetyl-glycyl-lysyl-phenylalanyl-lysyl-arginyl-prolyl-prolyl-leucyl-arginyl-arginyl-valyl-arginyl-amide
troponin i (104-115)
l-argininamide, n-acetylglycyl-l-lysyl-l-phenylalanyl-l-lysyl-l-arginyl-l-prolyl-l-prolyl-l-leucyl-l-arginyl-l-arginyl-l-valyl-
DTXSID40243555
(s)-1-(acetylglycyl-l-lysyl-l-phenylalanyl-l-lysyl-l-arginyl-l-prolyl)-n-((s)-1-(((s)-1-(((s)-1-(((s)-1-(((s)-1-amino-5-guanidino-1-oxopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amin
AKOS040746425
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.14 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (16.67%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
mastoparan
[no description available]		1.9710mastoparans;
peptidyl amide		antimicrobial agent
ConditionIndicatedRelationship StrengthStudiesTrials
ST Elevated Myocardial Infarction
[description not available]		02.2110
Athletic Injuries
Injuries incurred during participation in competitive or non-competitive sports.		02.2110
Aortic Dissection
[description not available]		02.2110
Precordial Catch
[description not available]		02.2110
ST Elevation Myocardial Infarction
A clinical syndrome defined by MYOCARDIAL ISCHEMIA symptoms; persistent elevation in the ST segments of the ELECTROCARDIOGRAM; and release of BIOMARKERS of myocardial NECROSIS (e.g., elevated TROPONIN levels). ST segment elevation in the ECG is often used in determining the treatment protocol (see also NON-ST ELEVATION MYOCARDIAL INFARCTION).		02.2110
Chest Pain
Pressure, burning, or numbness in the chest.		02.2110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0510
Innate Inflammatory Response
[description not available]		02.0510
Injury, Myocardial Reperfusion
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Cardiovascular Stroke
[description not available]		03.821
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		03.821
Cardiomyopathies, Primary
[description not available]		03.3911
Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).		03.3911
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9710